D&D Pharmatechs’ zabopegdutide shows rapid, weight-loss-independent MASH benefit

Phase 2positivezabopegdutidePositive

AI Analysis

Summary

D&D Pharmaceuticals published Phase II data showing zabopegdutide demonstrates rapid MASH benefit independent of weight loss in F1-F3 MASH and MASLD patients.

Clinical Trial Data

Phase

Phase II

Primary Endpoint

Met

Outcome Details

Rapid, weight-loss-independent MASH benefit demonstrated

Importance:6/10

Sentiment:

0.65

Phase 2MASHMASLDliver diseaseweight loss independent

Related Companies

$TRAX $RTSL $ARNA

Read the original article

Published by Clinical Trials Arena on July 27, 2026 2:05 PM

Read Original